[{"id":"0c72e324-a94b-4c79-b56d-8e07dee9bfbc","acronym":"CATUNIBLA","url":"https://clinicaltrials.gov/study/NCT04819399","created_at":"2021-03-29T12:52:24.159Z","updated_at":"2024-07-02T16:36:14.078Z","phase":"Phase 1","brief_title":"Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC","source_id_and_acronym":"NCT04819399 - CATUNIBLA","lead_sponsor":"Lindis Biotech GmbH","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Korjuny (catumaxomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-04-05"},{"id":"d8b1c0e5-1ab7-4efb-a01f-9602158b973a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01246440","created_at":"2021-01-18T05:01:11.794Z","updated_at":"2024-07-02T16:37:29.842Z","phase":"Phase 2","brief_title":"Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission","source_id_and_acronym":"NCT01246440","lead_sponsor":"Grupo Español de Investigación en Cáncer de Ovario","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Korjuny (catumaxomab)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2016-08-11"}]